Medication-related osteonecrosis of the jaw (MRONJ) is a severe devastating complication for which the exact pathogenesis is not completely understood. Multiple systemic and local factors may contribute to the development of MRONJ. A growing body of evidence supports diabetes mellitus (DM) as an important risk factor for this complication; however, the exact mechanism by which DM may promote MRONJ has yet to be determined. The current review elucidates the role of DM in the pathogenesis of MRONJ and the mechanisms by which DM may increase the risk for MRONJ. Factors related to DM pathogenesis and treatment may contribute to poor bone quality through multiple damaged pathways, including microvascular ischemia, endothelial cell dysfunction, reduced remodeling of bone, and increased apoptosis of osteoblasts and osteocytes. In addition, DM induces changes in immune cell function and promotes inflammation. This increases the risk for chronic infection in the settings of cancer and its treatment, as well as antiresorptive medication exposure, thus raising the risk of developing MRONJ. A genetic predisposition for MRONJ, coupled with CYP 450 gene alterations, has been suggested to affect the degradation of medications for DM such as thiazolidinediones and may further increase the risk for MRONJ.
Introduction
In the early 2000s, teams led by Marx and Ruggiero first reported nonhealing exposed bone in the maxillofacial region of patients treated with intravenous (IV) bisphosphonates (BPs) (Marx 2003; Ruggiero et al. 2004 ). Numerous studies have since been published on medication-related osteonecrosis of the jaw (MRONJ), mainly BP related. The cumulative incidence of this severe bone disease among antiresorptive users is estimated to range from 0.7% to 18% (Aragon-Ching et al. 2009; Migliorati et al. 2010 ). More recent antiresorptive therapies, including the denosumabreceptor activator of nuclear factor (NF)-κB ligand-RANKL monoclonal antibody inhibitor and antiangiogenic therapies, are associated with an increasing incidence of MRONJ (AAOMS 2014). Among the characteristics of BP and other antiresorptive therapies that have been suggested as risk factors for MRONJ are high drug potency, the IV route of administration, and extended duration of exposure (Bamias et al. 2005; Saad et al. 2012) . A number of patientrelated systemic factors have also been suggested, including cancer diagnosis, older age, chemotherapy treatment (antiangiogenic treatments), and factors relating to comorbidities (malnutrition, obesity, anemia, dialysis), lifestyle (alcohol, tobacco) , and pharmacotherapy, such as the use of glucocorticoids (Bamias et al. 2005; Barasch et al. 2011; AAOMS 2014) . Patient-related local risk factors include concomitant oral disease, poor oral hygiene, and major dental procedures (e.g., dental extraction) (Bamias et al. 2005; AAOMS 2014) .
Potential mechanisms for the development of MRONJ involve impaired bone repair, suppression of osteoclast activity, infection and inflammation, and impaired angiogenesis or vascular repair (Allen and Burr 2009) (Table 1) . This review describes the role of diabetes mellitus (DM) in the pathogenesis of MRONJ and the mechanisms by which DM may increase the risk for osteonecrosis ( Figure, Table  2 ). The main focus is microvascular ischemia of the bone, endothelial cell dysfunction and apoptosis, decreased bone turnover and remodeling, and increased apoptosis of osteoblasts and osteocytes. Factors that may contribute to the development of MRONJ, such as local factors, drug-related factors, immune suppression, inflammation, and genetic factors, are discussed.
Diabetes as a Risk Factor for MRONJ
Most studies investigating the relationship between DM and MRONJ reported a positive association (Khamaisi et al. 2007; Bocanegra-Pérez et al. 2012; Molcho et al. 2013; Watters et al. 2013; Berti-Couto et al. 2014 ); however, one study reported no association (Wilkinson et al. 2007) (Table  3 ). In a case-control study, DM was detected in 17% (33/191) of those with osteonecrosis of the jaw, compared with 11% (63/573) of the controls (Barasch et al. 2011) . In an observational study, DM was detected in 35% (15/44) of patients with MRONJ (Bocanegra-Pérez et al. 2012) . From a long-term follow-up of 109 individuals with MRONJ, a marginally significant correlation was found between poor prognosis and a diagnosis of DM (Watters et al. 2013 ). Among 68 patients with a progressive or unchanged clinical course of MRONJ, 18 (26.5%) had diabetes, compared to only 4 (9.4%) of the 29 with partial resolution or resolved MRONJ. Our team recently reported a prevalence of 58% (18/31) of DM (mainly type 2 DM) or impaired fasting glucose (IFG) among patients with MRONJ, compared to 12% among those treated with BP without MRONJ; diabetic nephropathy conferred an increased risk of MRONJ by up to 3.9-fold (Molcho et al. 2013) (Table 3) .
The current level of evidence is still premature and does not indicate a cause-and-effect relationship between DM and MRONJ. In a recently documented study of rats that were treated with alendronate and then underwent tooth extractions, osteonecrosis presented in 7 of 9 (78%) of those with streptozotocin-induced DM, compared to 0 of 11 of those without induced DM (Berti-Couto et al. 2014 ). The exact mechanism by which diabetes increases the risk of osteonecrosis of the jaw has yet to be determined.
Decreased Bone Turnover and Remodeling
Diabetic patients treated with antiresorptive medications are challenged by both the metabolic disorder and by the potential for bone remodeling complications conferred by the treatment. DM specifically has been found to have a profound effect on bone metabolism via reductions in bone turnover, in remodeling, and in alveolar bone formation. Several clinical studies showed that while low bone mineral density (BMD) is consistently observed in type 1 diabetes (T1DM) at the radius and femur, BMD in type 2 diabetes (T2DM) is similar to or higher than that in nondiabetic persons (Isidro and Ruano 2010) . Altered BMD in diabetic patients, together with bone quality deterioration, may be linked to an increased risk for fractures. Multiple pathways can affect bone metabolism in DM and may explain the deterioration in bone quality, among them changes in insulin levels, elevated levels of advanced glycation end products (AGEs) in collagen, increased urinary excretion coupled with lower intestinal absorption of calcium, inappropriate homeostatic response of parathyroid hormone secretion, complex alterations of vitamin D regulation, reduced renal function, lower insulin-like growth factor-1 (IGF-1), microangiopathy, and inflammation (Isidro and Ruano 2010) . Osteoblasts, which were found to express insulin receptors, mediate an anabolic effect of insulin on the bone. By promoting bone formation, bone density and strength are maintained or increased (Thrailkill et al. 2005) . Poor metabolic control can exert deleterious effects on the bone through a number of mechanisms. Chronic hyperglycemia leads to glycosylation of proteins, producing AGEs in various tissues, including bone. AGEs contribute to the inhibition of osteoblastic adhesion to the bone matrix, which can exacerbate diabetic osteopenia by inhibiting growth, differentiation, and mineralization in the bone matrix (McCarthy et al. 2004 ). These effects are enhanced by impaired calcium homeostasis and abnormalities in vitamin D metabolism, which are associated with DM. Reduced hemostasis was suggested to induce negative feedback on the parathyroid gland, resulting in hypoparathyroidism and leading to reduced parathyroid hormone (PTH) secretion and further negative calcium balance (McNair et al. 1981 ). Glucosuric-induced osmotic diuresis causes renal calcium leak, which also contributes to negative calcium balance (Okazaki et al. 1997 ). In addition, hyperosmolarity induced by hyperglycemia suppresses the expression of osteocalcin, MMP-13, and vascular endothelial growth factor (VEGF), genes associated with osteoblast maturation (Botolin and McCabe 2006) . Accumulating evidence indicates that the glucose-lowering medications, thiazolidinediones (TZDs), may negatively affect bone metabolism. TZDs induce bone loss by affecting the bone remodeling process, suppressing new bone formation by osteoblasts, and increasing bone resorption by osteoclasts. Furthermore, TZDs decrease BMD and bone volume, as well as induce changes in bone microarchitecture (Rzonca et al. 2004) . In marrow cells of mesenchymal lineage, TZDs suppressed bone anabolic signaling by decreasing activity of Wnt and by transforming growth factor-β (TGF-β)/bone morphogenic protein and IGF-1 pathways, while inducing production of RANKL (Shockley et al. 2009 ). In patients with T2DM, TZDs decreased serum osteocalcin and femoral and radial BMD (Kanazawa et al. 2010 ). In addition, a high risk for fractures was described in T2DM women older than 65 years who were treated with TZDs (Habib et al. 2010 ).
Increased Apoptosis of Osteoblasts and Osteocytes
Osteocyte apoptosis was found to be more prevalent in histological specimens of patients diagnosed with MRONJ than in specimens of healthy bone (Lesclous et al. 2009 ). Associations between changes in bone metabolism and elevated blood glucose levels support a role of both T1DM and T2DM in MRONJ. These changes include inhibition of osteoclast differentiation and function, as well as induction of osteoblast and osteocyte apoptosis. AGEs are increased in individuals with DM and are believed to contribute to the development and progression of chronic complications that include a decrease in bone quality. In an in vitro system, Gangoiti et al. (2013) reported that AGEs induce disruption in the osteoblastic actin cytoskeleton and alterations in cell morphology. The subsequent decrease in cell-substratum interactions was shown to increase apoptosis of osteoblasts and decrease osteoblastic proliferation; the addition of alendronate enhanced such activity (Gangoiti et al. 2013 ). Many of the effects of AGEs are receptor dependent and involve a multiligand member of the immunoglobulin superfamily of cell surface molecules. The best characterized of these is the receptor for advanced glycation end products (RAGE). Based on studies of RAGE-deficient mice, RAGE appears to play a central role in oral infection, exaggerated inflammatory host responses, and the destruction of alveolar bone in DM (Lalla et al. 2001 ). Sorbitol, a by-product of high-glucose flux through the polyol pathway, has been implicated in the development of DM complications. Inaba (2006) suggested that intracellular sorbitol accumulation in individuals with DM might be involved in the development of osteoblast dysfunction and osteoclast formation. This was further supported by the protective effect of aldose reductase inhibitor against the development of galactose-induced bone diseases.
Increased Inflammation
Periodontal disease is the most prevalent oral complication of T2DM. T2DM confers a 2.81 increased risk of destructive periodontitis (Papapanou 1996) . Both rat models and clinical settings demonstrated that decreased metabolic control in T2DM negatively affects all clinical measures of periodontal health and disease severity (Cutler et al. 1999) . A bidirectional relationship between DM and periodontitis seems very likely; periodontal diseases can aggravate insulin resistance and adversely affect glycemic control, and periodontal treatment improves glycemic control in T2DM (Stanko and Izakovicova Holla 2014) .
Activated T and B cells in the gingival tissues are the primary sources of RANKL, which induces osteoclastogenesis, osteoclast activation, and bone loss in periodontitis (Kawai et al. 2006) . Inhibiting the function of RANKL produced by activated T cells can prevent alveolar bone loss (Lin et al. 2011) . These studies provide strong evidence that T-cell activation mediates bone loss via recruitment and activation of osteoclasts. Elevated levels of high-sensitivity C-reactive protein in gingival crevicular fluid were recently reported in T2DM patients with chronic periodontitis (Kalra et al. 2013 ). In addition, interleukin (IL)-6 and the RANK/osteoprotegerin ratio were higher in the oral mucosa of patients with jaw necrosis than in those without (Mozzati et al. 2013 ).
Altered Immune Responses
BPs share structural homologies with previously identified γδ T-cell ligands (Kunzmann et al. 2000) . Long-term or high-dose use of BPs has been associated with loss of peripheral blood Vγ9Vδ2 T cells; this is apparently due to druginduced immune dysfunction. Kalyan et al. (2014) recently reported that neutrophils present in human peripheral blood readily take up zoledronate and that this phenomenon is associated with the potent immune suppression of human peripheral blood Vγ9Vδ2 T cells. Furthermore, BPs were shown to inhibit T-lymphocyte activation and proliferation, to suppress monocyte production of various proinflammatory cytokines (Sansoni et al. 1995) , and to increase production of proinflammatory cytokines by lymphocytes (Coxon et al. 2006) . Neutrophil chemotaxis and survival were found to be compromised following exposure to BPs (Kuiper et al. 2012) . The result was altered activity and chronic tissue damage that can lead to MRONJ. Similarly, reduced neutrophil activity and impaired chemotaxis were demonstrated in individuals diagnosed with MRONJ, independent of BP treatment (Favot et al. 2013 ). Furthermore, compromised macrophage function at MRONJ sites was also recently demonstrated (Hoefert et al. 2014) . In patients with metastatic prostate cancer treated with docetaxel and zoledronic acid, leukopenia induced by chemotherapy was suggested as a risk factor for MRONJ, perhaps by aggravating oral cavity infection mediated by mucositis (Miyazaki et al. 2012 ). Furthermore, Kikuiri et al. (2010) showed that systemic infusion of mesenchymal stem cells (MSCs) in MRONJ-like mice prevents and cures MRONJ-like disease, possibly via induction of peripheral tolerance-specifically, by inhibition of Th17 and enhancement of Treg cells. This demonstrates an immunity-based mechanism of MRONJ disease and supports the rationale for in vivo immune-modulatory therapy for MRONJ, using Tregs or MSCs.
Diabetes induces changes in neutrophil, monocyte, and macrophage function. Neutrophil adherence, chemotaxis, and phagocytosis are often impaired. Conversely, the monocyte-macrophage cell line may be hyperresponsive to bacterial antigens, resulting in significantly increased production of proinflammatory cytokines (Nassar et al. 2007 ). Elevated levels of monocyte chemoattractant protein-1 (MCP-1) in gingival tissues, increased gingival inflammatory cell infiltration, and alveolar bone loss were reported in rats with either DM or periodontitis (Sakallioğlu et al. 2008) .
Factors contributing to an altered immune response may increase the risk for chronic infection in the setting of DM, cancer and its treatment, and BP exposure, thereby increasing the risk of developing MRONJ in this population.
Angiogenesis, Vascularization, and Endothelial Damage
Antiresorptive medications may inhibit angiogenesis by impairing endothelial cell (EC) functions. BPs were shown to inhibit EC proliferation, leading to altered EC adhesion and migration (Wood et al. 2002) . Zoledronic acid was found to inhibit integrin-mediated adhesion and migration in human EC (Bezzi et al. 2003) . Furthermore, reduced proliferation, increased apoptosis, and decreased capillary-like tube formation in ECs treated with BPs was described (Fournier et al. 2002) . Among patients treated with BPs, proangiogenic factors-specifically, hydroxymethylglutaryl coenzyme A reductase and VEGF-were reduced (Mozzati et al. 2013) . Histological evaluation of MRONJ tissue revealed decreased p63 gene expression, indicating a reduction in basal cell progenitors and leading to impaired healing of the oral mucosa (Scheller et al. 2011) . In patients with multiple myeloma (MM) and MRONJ, EC apoptosis was reported to increase following administration of BPs. This supports the hypothesis that BPs inhibit angiogenesis by interfering with EC proliferation and survival, leading to loss of blood vessels and avascular necrosis (Allegra et al. 2010) .
The above findings demonstrate antiangiogenic properties of potent BPs, which may contribute to the treatment of malignant bone disease, as well as to other diseases with an angiogenic component. Several studies assessed the relationship between MRONJ and other antiangiogenic drugs. A number of anecdotal publications documented MRONJ in patients treated with bevacizumab (Christodoulou et al. 2009 ), a humanized monoclonal antibody against VEGF; however, investigation of the databases of 3 large prospective trials of advanced breast cancer, comprising 3,560 patients, did not reveal a significant effect of bevacizumab on the risk of MRONJ, beyond that of BPs alone (Guarneri et al. 2010) . Antiangiogenic agents, including sunitinib and sorafenib, in combination with bisphosphonates, have been suggested to induce osteonecrosis of the jaw more frequently than do BPs alone (Christodoulou et al. 2009 ). A particularly high rate of 18% MRONJ was noted in patients with prostate cancer on zoledronic acid treated with a drug regimen combining bevacizumab, docetaxel, thalidomide, and prednisone (Aragon-Ching et al. 2009 ).
Microvascular ischemia of the bone is recognized in DM. This is especially relevant since oxidative damage plays a fundamental pathogenic role in MRONJ, as established by detection of mitochondrial DNA damage in the gingival tissue of patients with periodontitis (Hill 1998) and increased systemic markers of oxidative stress (Bagan et al. 2014) . Okamoto et al. (2002) showed that BPs inhibit AGEinduced angiogenesis processes via DNA synthesis, as well as through the formation of microvascular endothelial cells. This is accelerated in individuals with diabetes, most likely leading to poorly functioning blood vessels. That study also demonstrated the inhibition of transcriptional activation of RANK and activator protein-1, as well as the subsequent upregulation of VEGF messenger RNA levels in AGEexposed endothelial cells. Decreased endothelial VEGF expression and microvessel density were detected in gingival samples from patients with generalized, severe, and chronic periodontitis with T2DM (Aspriello et al. 2009 ). These findings may result from insulin resistance and endothelial dysfunction, which often present in patients with T2DM. More recently, using a technique for in vivo detection of free radical reactions and laser Doppler flowmetry to evaluate gingival reactive hyperemia, Sugiyama et al. (2012) found that vascular endothelial function was decreased in DM and in periodontal disease due to increasing oxidative stress in gingival circulation.
Our recent findings (Molcho et al. 2013 ) of higher rates of microvascular complications among MRONJ patients with DM or IFG than among those without DM or IFG suggest an increased probability of developing MRONJ among individuals with microvascular complications of DM.
Genetic Factors
In individuals with MM treated with antiresorptive therapy, 54,600 genes were analyzed in an exploratory transcriptional profiling of mononuclear cells in peripheral blood (Raje et al. 2008 ). Among the MM patients with MRONJ, downregulation of genes involved in osteoclast or osteoblast signaling, activation, or differentiation was demonstrated, as well as upregulation of osteoclast-inhibiting factors. A single-nucleotide polymorphism (SNP) analysis, comparing 24 MM patients with MRONJ to 651 treated with BP and without MRONJ, revealed 4 SNPs that were associated with MRONJ: rs1934951, rs1934980, rs1341162, and rs17110453 (Sarasquete et al. 2008 ). The SNP rs1934951 showed a particularly high risk for developing MRONJ, with an odds ratio (OR) of 12.75. All SNPs mapped within the cytochrome P450 (CYP 450), by subfamily 2C polypeptide 8 genes (CYP2C8). CYP2C8 is responsible for the metabolism of several drugs, including TZDs. Thus, variability in genes encoding CYP2C8 may affect drug pharmacokinetics, including glucose-lowering drugs (Ingelman-Sundberg et al. 2007 ). BP taken up by osteoclasts inhibits the activity of the enzyme farnesyl pyrophosphate synthase, which is involved in cholesterol synthesis. This enzyme also prevents lipid modification of signaling proteins, which ultimately induces osteoclast apoptosis. These enzymatic factors may contribute to the high bone turnover compromise in susceptible bones, such as the maxilla and mandible, and to the development of MRONJ. Additional genetic polymorphisms to be considered are the metabolic enzymes involved in oral health and inflammation: glutathione transferases M1 and T1, N-acetyl transferase 2, and CYP 1A1. The genes that encode these metalloproteases (involved in periodontal tissue remodeling and degradation), cytokines (involved in inflammation), prothrombin, and DNA repair activities, may be associated with susceptibility to dental diseases that have a genetic base (Baldi et al. 2009 ).
Genetic pathways involved in drug degradations in prominent members of the CYP 450 isoenzyme family were found to be altered in T2DM, thus further challenging the diabetic patient treated with BPs. A significant increase in the prevalence of CYP2C8 mutations in T2DM patients was reported. For example, the CYP2C8 *4 allele was found to be mutated in 15% and 2% of those with and without DM, respectively (Weise et al. 2010 ). These differences may result in altered drug degradation and efficacy. In vitro analysis showed different alleles to result in altered metabolism of the TZD, pioglitazone (Muschler et al. 2009 ).
Future Directions
The identification of numerous cofactors associated with MRONJ has prompted the initiation of hypothesis-driven research aimed to elucidate the pathogenesis of this debilitating disease (Table 1) . Accumulating evidence supports an association between DM and MRONJ (Table 3) ; however, prospective clinical trials are needed to define this relationship, specifically with modern antiresorptive medications. Angiogenesis and endothelial dysfunction in individuals with DM, as well as the relationship to MRONJ, need to be investigated in the setting of tooth extraction. Alterations of vasculature reconstitution should be assessed in the setting of suppression of angiogenesis and hypoxia-related gene expression. More accurate identification of patients who are at particularly high risk for developing MRONJ is needed (Figure, Table 2 ). This may be accomplished by defining a molecular risk panel that will enable a more profound consideration of the antiresorptive treatment in such patients, including those with DM. Improved therapy of MRONJ has a promising venue in the field of stem cell therapy. Further exploration of MSC therapy in human clinical trials is needed, since stem cells can induce ectopic bone formation as well as angiogenesis. Stem cells might become a promising tool in the treatment of MRONJ.
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